Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation phenotype BEFREE Mutations in KRAS and TP53 are common in colorectal carcinogenesis and are associated with resistance to therapy. 23456389 2013
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker phenotype BEFREE Deregulated Her2/ErbB2 receptor tyrosine kinase drives tumorigenesis and tumor progression in a variety of human tissues. 17982484 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation phenotype BEFREE Our data indicate that genetic variants in CDKN2A, and possibly nearby genes, may be associated with ESCC and several other tumours, further highlighting the importance of 9p21.3 genetic variants in carcinogenesis. 23361049 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker phenotype BEFREE Here we explore how nutrients and caloric intake may influence the KRAS-driven ductal carcinogenesis through mediators of metabolic stress, including autophagy in presence of TP53, advanced glycation end products (AGE) and the receptors (RAGE) and ligands (HMGB1), as well as glutamine pathways, among others. 24704294 2015
Entrez Id: 4780
Gene Symbol: NFE2L2
NFE2L2
0.400 Biomarker phenotype BEFREE Effects of Nrf2 silencing on oxidative stress-associated intestinal carcinogenesis in mice. 26899729 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker phenotype BEFREE Detection of promoter hypermethylation of cancer-related genes may be useful for cancer diagnosis or the detection of recurrence. p16, an inhibitor of the cyclin D-dependent protein kinases, is a classical tumor suppressor gene, and its inactivation is closely associated with carcinogenesis. p16 hypermethylation could be detected in each stage, which is consistent with the finding that aberrant methylation of p16 is a very early event in carcinogenesis. 12907744 2003
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker phenotype BEFREE A combination of sequence analysis, reporter gene assays, quantitative real-time PCR, electrophoretic gel mobility shift assays and immunoblot analysis further confirmed the four AP-2gamma target genes in carcinogenesis group: ErbB2, CDH2, HPSE and IGSF11. 19671168 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression phenotype BEFREE Expression of two viral oncogenes, E6 and E7, in epithelial stem cells is required to initiate and maintain cervical carcinogenesis and results in significant overexpression of the cellular p16INK4a protein. 11790875 2001
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker phenotype BEFREE These data provided direct evidence that HER2/neu signaling is essential for tumorigenicity of NSCLC cells, and suggested that siRNAs targeted to HER2/neu may provide a novel therapeutic strategy in the treatment of NSCLC, especially when combined with traditional therapeutics or via development of vector-based siRNAs of multiple targets that synergistically contribute to carcinogenesis, e.g.EGFR and HER2/neu. 19339104 2009
Entrez Id: 857
Gene Symbol: CAV1
CAV1
0.400 Biomarker phenotype BEFREE Functionally, we demonstrate that fibroblasts co-cultured with MCF7 breast cancer cells acquire a cancer associated fibroblast phenotype, characterized by Cav-1 downregulation, increased expression of myofibroblast markers and extracellular matrix proteins, and constitutive activation of TGFβ/Smad2 signaling. siRNA-mediated Cav-1 downregulation mimics several key changes that occur in co-cultured fibroblasts, clearly indicating that a loss of Cav-1 is a critical initiating factor, driving stromal fibroblast activation during tumorigenesis. 20562526 2010
Entrez Id: 857
Gene Symbol: CAV1
CAV1
0.400 AlteredExpression phenotype BEFREE Although none of these four genes showed significant expression differences between PCa ERG+ and PCa ETS-, CAV1, IGFBP3 and TGFBR2 were less expressed in PCa in an independent series of 56 PCa and 15 NPT, as also observed for ECRG4 and LDOC1, suggesting a role in prostate carcinogenesis in general. 23185447 2012
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 GeneticVariation phenotype BEFREE Further investigation of the CTH gene in colorectal carcinogenesis with regards to KRAS and BRAF mutations or other molecular characteristics of the tumor may be warranted. 29694444 2018
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker phenotype BEFREE CDKN2 is not deleted with high frequency in primary breast carcinomas, and the p16 gene does not play a role in breast carcinogenesis via this mechanism. 9259969 1997
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker phenotype BEFREE Targeting cytokine networks in KRAS-driven tumorigenesis. 24928447 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker phenotype BEFREE To investigate the role of α3β1 in HER2-driven tumorigenesis in vivo, we generated a HER2-driven MMTV-cNeu mouse model of mammary tumorigenesis with targeted deletion of Itga3 (Itga3 KO mice). 31101121 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 PosttranslationalModification phenotype BEFREE Silencing of the p16 gene by methylation of its promoter CpG island was suggested as a unique molecular mechanism in the carcinogenesis of PRC compared with MRC or PC. 16465421 2006
Entrez Id: 4780
Gene Symbol: NFE2L2
NFE2L2
0.400 Biomarker phenotype BEFREE In conclusion, our findings revealed novel functions for Nrf2 in the regulation of redox status and cell proliferation, and that intracellular GSH levels and AKT signaling are required for this process, a new viewpoint by which to comprehend the role and underlying mechanism of Nrf2 in tumorigenesis. 28260004 2017
Entrez Id: 857
Gene Symbol: CAV1
CAV1
0.400 Biomarker phenotype BEFREE Moreover, changes in caveolin-1 play an important role in tumorigenesis and inflammatory processes. 30742851 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression phenotype BEFREE No association was established between occurrence of genetic aberrations at 9p21 and tumor stage or grade, supporting previous suggestions that CDKN2A/ARF inactivation is an early event in bladder carcinogenesis. 12538475 2003
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.400 Biomarker phenotype BEFREE Mutations in EGFR, ERBB2, NRAS, and BRAF are early clonal genomic events during carcinogenesis of lung adenocarcinoma, whereas TP53 and cell mobility, gap junction, and metastasis-related genes may be late events associated with subclonal diversification and neoplastic progression. 31446140 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 PosttranslationalModification phenotype BEFREE To investigate the molecular mechanism of p16 gene inactivation in gastric carcinogenesis, we examined the methylation status of p16 in GC using methylation-specific PCR. 10830779 2000
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker phenotype BEFREE Genetic disruption of Cdkn2a(p19Arf) (hereafter Arf) alone predisposes mice to tumorigenesis, demonstrating that Arf is a tumour-suppressor gene in mice. 11544530 2001
Entrez Id: 406935
Gene Symbol: MIR143
MIR143
0.400 Biomarker phenotype BEFREE MiR-143-3p may suppress tumorigenesis in PDAC by targeting KRAS. 31521891 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker phenotype BEFREE Our data highlight a pivotal role of the cooperative interaction between obesity-ensuing HFD and oncogenic KRAS in driving the heightened aerobic glycolysis during pancreatic tumorigenesis and suggest that in addition to directly targeting KRAS and aerobic glycolysis pathway, strategies to target the upstream of KRAS hyperactivation may bear important therapeutic value. 30819189 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker phenotype BEFREE The molecular mechanisms of oncogenesis in mesothelioma involve the loss of negative regulators of cell growth including p16(INK4a). 12399123 2002